CorMedix (NASDAQ:CRMD) CFO Susan Blum Buys 5,000 Shares of Stock

CorMedix Inc (NASDAQ:CRMD – Get Free Report) CFO Susan Blum acquired 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 19th. The shares were acquired at an average cost of $4.58 per share, for a total transaction of $22,900.00. Following the purchase, the chief financial officer directly owned 129,315 shares of the company’s stock, valued at $592,262.70. This represents a 4.02% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

CorMedix Price Performance

Shares of NASDAQ CRMD opened at $5.27 on Friday. CorMedix Inc has a fifty-two week low of $4.47 and a fifty-two week high of $13.02. The company has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $7.49. The company has a market capitalization of $419.18 million, a price-to-earnings ratio of 3.74, a P/E/G ratio of 1.11 and a beta of 1.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.43.

CorMedix (NASDAQ:CRMD – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $54.52 million for the quarter, compared to analysts’ expectations of $51.76 million. CorMedix had a net margin of 15.49% and a return on equity of 26.70%. Analysts expect that CorMedix Inc will post 0.44 EPS for the current fiscal year.

Institutional Investors Weigh In On CorMedix

Several institutional investors and hedge funds have recently made changes to their positions in CRMD. Advisors Asset Management Inc. purchased a new stake in CorMedix during the 3rd quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CorMedix in the third quarter worth $31,000. Kestra Advisory Services LLC raised its stake in shares of CorMedix by 142.9% in the first quarter. Kestra Advisory Services LLC now owns 10,200 shares of the company’s stock worth $69,000 after purchasing an additional 6,000 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of CorMedix during the second quarter valued at $85,000. Finally, Allworth Financial LP bought a new position in shares of CorMedix during the second quarter valued at $88,000. Institutional investors own 34.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CRMD shares. UBS Group set a $19.00 target price on CorMedix in a report on Tuesday, November 10th. Weiss Ratings downgraded CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, November 10th. Royal Bank Of Canada lifted their price target on CorMedix from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Citigroup reaffirmed a “market outperform” rating on shares of CorMedix in a research report on Tuesday, November 10th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $13.00 price target (down from $15.00) on shares of CorMedix in a research note on Friday, November 13th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, CorMedix presently has an average rating of “Moderate Buy” and a consensus target price of $15.22.

View Our Latest Report on CRMD

About CorMedix

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Featured Stories

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.